

A Partnership Including
Professional Corporations
600 Thirteenth Street, N.W.
Washington, D.C. 20005-3096
202-756-8000
Facsimile 202-756-8087
www.mwe.com

Robert B. Nicholas
Attorney at Law
rnicholas@mwe.com
202-756-8170

Boston
Chicago
London
Los Angeles
Miami
Moscow
New York
Orange County
Silicon Valley
Vilnius
Washington, D.C.

MCDERMOTT, WILL & EMERY

September 13, 2002

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane (Room 1061)
Rockville, Maryland 20852


Re: In the Matter of Notice of Hearing: Proposal to Withdraw
Approval of New Animal Drug Application for Enrofloxacin
for Poultry ("Enrofloxacin Hearing")
FDA Docket: 00N-1571

Dear Sir/Madam:

Enclosed for filing please find an original and one copy of Respondent Bayer Corporation's Motion to Supplement Document Submission under 21 C.F.R § 12.85 and corresponding documents related to that Motion.

Please call with any questions.

Sincerely,


Robert B. Nicholas

RBN:nab
Enclosures

5772 02 SEP 13 11:36

**UNITED STATES OF AMERICA
BEFORE THE FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES**

_____)	
)	
)	
In the Matter of:)	FDA DOCKET: 00N-1571
)	DATE: September 13, 2002
Enrofloxacin for Poultry: Withdrawal)	
of Approval of Bayer Corporation's)	
New Animal Drug Application)	
(NADA) 140-828 (Baytril))	
)	
)	
)	
_____)	

**RESPONDENT BAYER'S MOTION TO SUPPLEMENT
DOCUMENT SUBMISSION UNDER 21 C.F.R. § 12.85**

Pursuant to 21 C.F.R. § 12.85(c) Respondent Bayer Corporation ("Bayer" or "Respondent") respectfully requests approval to supplement its document submission under 21 C.F.R. § 12.85(a). The subject documents numbered B-1170 through B-1507 have been filed with the Dockets Management Branch.

21 C.F.R. § 12.85(a) requires Respondent to submit to the Dockets Management Branch documents in Respondent's files containing factual information which relate to the issues (§ 12.85(a)(2)) as well as all other documentary data and information relied upon (§ 12.85(a)(3)).

In accordance with 21 C.F.R § 12.85(c) and the July 17, 2002 Order entered in this matter, Bayer seeks to supplement its 12.85 document submission. 21 CFR § 12.85(c) states:

Submissions required by ... this section may be supplemented later in the proceeding, with the approval of the presiding officer, upon a showing that the material contained in the supplement was not reasonably known or available when the submission was made or

that the relevance of the material contained in the supplement could not reasonably have been foreseen.

Furthermore, the July 17, 2002 Order in this matter states that:

21 C.F.R. § 12.85(c) indicates that the required submissions "... may be supplemented later in the proceeding, with the approval of the presiding officer, upon a showing that the material ... was not reasonably known or available ... or that the relevance of the material contained in the supplement could not reasonably been foreseen (sic)." (Emphasis added). It appears that the use of the word "may" allows the submissions to be voluntary and that the parties may therefore voluntarily limit their Section 12.85 supplements to relevant material.

Order at 1.

The subject documents each fall in one or more of the following categories:

- i) documents not reasonably known to Respondent at the time of its April 22, 2002 filing pursuant to § 12.85;
- ii) documents not reasonably available to Respondent at the time of its April 22, 2002 filing pursuant to § 12.85;
- iii) documents whose relevance was not reasonably foreseen by Respondent at the time of its April 22, 2002 filing pursuant to § 12.85.

The subject documents are now known by and available to Respondent and Respondent believes that each is relevant to the issues set for hearing herein. Respondent anticipates relying on the data and information contained in the subject documents at the hearing in this matter. As such, it is reasonable and appropriate that the documents be added to the docket as part of Respondent's § 12.85 filing.

In conclusion, these documents are relevant to the issues of the hearing and have been published, acquired, or come to the attention of Bayer, since its last submission.

Respectfully submitted,



Robert B. Nicholas
James H. Sneed
Gregory A. Krauss
M. Miller Baker
McDERMOTT, WILL & EMERY
600 Thirteenth Street, N.W.
Washington, D.C. 20005
(202) 756-8000

Attorneys for Bayer


CERTIFICATE OF SERVICE

I hereby certify that a copy of Respondent Bayer's Motion To Supplement Document Submission Under 21 CFR § 12.85 was mailed this 13th day of September, 2002, via first-class mail, postage pre-paid to:

Kent D. McClure
Animal Health Institute
1325 G Street, N.W., Suite 700
Washington, D.C. 20005

I hereby certify that a copy of Respondent Bayer's Motion To Supplement Document Submission Under 21 CFR § 12.85 was e-mailed and also mailed, postage pre-paid, this 13th day of September, 2002 to:

Nadine R. Steinberg, Esquire
Food and Drug Administration
Office of General Counsel (CGF-1)
5600 Fischers Lane, Room 7-77
Rockville, MD 20857



Robert B. Nicholas

**UNITED STATES OF AMERICA
BEFORE THE FOOD AND DRUG ADMINISTRATION
DEPARTMENT OF HEALTH AND HUMAN SERVICES**

In the Matter of:

**Enrofloxacin for Poultry:
Withdrawal of Approval of
New Animal Drug Application
NADA 140-828**

FDA DOCKET: 00N-1571

ORDER

By motion filed September 13, 2002, Respondent Bayer Corporation seeks to supplement its documentary submission pursuant to 21 C.F.R. § 12.85(c).

Bayer states that the documents subject to its motion are related to the issues and have been published, acquired or come to the attention of Bayer since its April 22, 2002 submission.

Accordingly, the motion will be granted.

It is ORDERED, that Respondent Bayer's Motion to Supplement Submission Under 21 CFR § 12.85 is GRANTED.

DATED this the ___ day of September, 2002.

Daniel J. Davidson
Administrative Law Judge